Introduction Coronavirus disease 2019 (COVID-19) is a major social and economic challenge, devastating the health care system in several countries around the world. Mortality scores are important as they can help health care professionals to plan treatment as per the patients' condition for proper resource allocation. When it comes to patients, it provides invaluable information for implementing advance directives. The aim of the study is to validate mortality scores for predicting in-hospital mortality in patients with COVID-19. Methodology This was a retrospective cohort study that included data from three tertiary care hospitals in Karachi, Pakistan. Data of patients diagnosed with confirmed COVID-19 infection and hospitalized in Ziauddin Hospital, Aga Khan Hospital, and Liaquat National Hospital were enrolled in the study from November 1, 2020, to April 30, 2021. Data was extracted from the hospital management information system (HMIS) using a structured questionnaire. Results Overall, 835 patients were included in the final analysis. The mean age of patients was 53.29 (SD ± 15.17) years, and 675 patients (80.72%) were males. The sensitivity of the CALL score is highest among all four scores, i.e., 77.25%, and the quick Sequential Organ Failure Assessment (qSOFA) score has the lowest sensitivity (59.79%). However, CALL has the lowest specificity (58.04%), while qSOFA has the highest specificity (73.91%). However, MulBSTA and CRB-65 have a sensitivity of 70.11% and 64.96%, respectively. Conclusion The current study showed that the CALL score had better sensitivity as compared to other mortality scores.

How to cite this retraction

This article has been retracted due to the unknown origin of the data, lack of verified IRB approval, and purchased authorships. While not listed as an author, it was discovered that Rahil Barkat wrote and coordinated the submission of this article. Mr. Barkat was involved in data theft and misuse in two recently published Cureus articles, which have since been retracted.

Introduction: Charlson Comorbidity Index (CCI) is a simple, validated, and readily acceptable method of determining the risk of mortality from comorbid disease. It has been used as a predictor of long-term survival and prognosis. The aim of this study is to determine the impact of CCI score on mortality in COVID-19 hospitalized patients and test the efficacy of the CoLACD score (COVID-19 lymphocyte ratio, age, CCI score, dyspnoea) in predicting mortality among hospitalized COVID-19 patients.Methodology: It was a retrospective cohort, and the data of this study were gathered from two tertiary hospitals of Karachi, including Liaquat National Hospital and Ziauddin Hospital. Data of patients hospitalized in any of these tertiary care hospitals and diagnosed with confirmed COVID-19 infection were used in the study from January 15, 2021, to April 30, 2021.Results: The mean age of participants was 53.22 (±14.21) years. The majority of participants were males (74.91%). Predictors of mortality include CCI score, age of participants, D-dimer, smoking status, and shortness of breath. The sensitivity of this CoLACD score was 80.23%, and specificity was 50.23% (diagnostic accuracy is 60.45%). The negative predictive value (NPV) of this test was 39.44%, and the positive predictive value (PPV) was 83.01%. Conclusion:Our study showed that CCI can be used in a clinical setting to achieve a prediction of mortality in COVID-19 patients.

How to cite this retraction